Results 11 to 20 of about 16,883 (239)

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología (English Edition), 2023
Kidney disease is frequent in HIV-patients. We present a case of a 44-year-old woman, with known uncontrolled HIV infection and chronic kidney disease due to HIV-associated nephropathy.
Rui Barata, Bernardo Marques da Costa, David Navarro, Marco Mendes, Cecília Silva, Mário Góis, Helena Sousa, Fernando Nolasco   +7 more
doaj   +3 more sources

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses, 2023
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist.
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller   +16 more
doaj   +1 more source

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Southern African Journal of HIV Medicine, 2022
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women.
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi   +7 more
doaj   +1 more source

Dolutegravir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Metabolites, 2022
Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir
Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno   +11 more
doaj   +1 more source

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Wellcome Open Research, 2021
Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs).
Rulan Griesel, Andrew Hill, Graeme Meintjes, Gary Maartens   +3 more
doaj   +1 more source

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

BMC Public Health, 2020
Background Despite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes.
Yussif Alhassan, Adelline Twimukye, Thoko Malaba, Catherine Orrell, Landon Myer, Catriona Waitt, Mohammed Lamorde, Andrew Kambugu, Helen Reynolds, Saye Khoo, Miriam Taegtmeyer   +10 more
doaj   +1 more source

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

Journal of Global Antimicrobial Resistance, 2020
Objectives: In the HIV-1-positive population, a paradigm shift from three-drug regimens (3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment is beginning to take place, supported virologically by the availability of ...
Valeria Cento, Carlo Federico Perno
doaj   +1 more source

The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study

The Lancet Global Health, 2022
Background: Emerging evidence suggests a possible association between hyperglycaemia and use of dolutegravir, a preferred first-line antiretroviral agent in sub-Saharan Africa.
Daphine Namara, MBChB, Jeremy I Schwartz, MD, Andrew K Tusubira, MPH, Willi McFarland, ProfMD, Caroline Birungi, MMed, Fred C Semitala, MMed, Martin Muddu, MMed   +6 more
doaj   +1 more source

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV Research & Clinical Practice, 2021
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofovir ...
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk   +11 more
doaj   +1 more source